Estimated Incidence of Symptomatic Lyme Borreliosis Cases in Lublin, Poland in 2021.

Lyme borreliosis Poland incidence seroprevalence surveillance tick-borne disease

Journal

Microorganisms
ISSN: 2076-2607
Titre abrégé: Microorganisms
Pays: Switzerland
ID NLM: 101625893

Informations de publication

Date de publication:
03 Oct 2023
Historique:
received: 01 09 2023
revised: 28 09 2023
accepted: 02 10 2023
medline: 28 10 2023
pubmed: 28 10 2023
entrez: 28 10 2023
Statut: epublish

Résumé

Lyme borreliosis (LB), the most common tick-borne disease in Europe, is endemic to Poland. Despite public health surveillance with mandatory reporting of LB cases by physicians and laboratories, many symptomatic LB cases are not included in surveillance in Poland. We estimated the extent of the under-ascertainment of symptomatic LB cases via surveillance in the Polish province of Lublin to better understand Poland's LB burden. The number of incident symptomatic LB cases in Lublin in 2010 was estimated from two seroprevalence studies conducted among adults in Lublin, as well as estimates of the proportion of asymptomatic LB cases and the duration of LB antibody persistence. The estimated number of incident symptomatic LB cases was compared to the number of surveillance-reported cases in Lublin to derive an under-ascertainment multiplier. This multiplier was applied to the number of surveillance-reported cases in 2021 to estimate the number and population-based incidence of symptomatic LB cases in Lublin in 2021. We estimate that there are 5.9 symptomatic LB cases for every surveillance-reported LB case in Lublin. Adjusting for under-ascertainment, the estimated number of symptomatic LB cases in Lublin in 2021 was 6204 (population-based incidence: 467.6/100,000). After adjustment for under-ascertainment, the incidence of symptomatic LB in Lublin, Poland, is high.

Identifiants

pubmed: 37894139
pii: microorganisms11102481
doi: 10.3390/microorganisms11102481
pmc: PMC10608808
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Pfizer (United States)
ID : N/A
Organisme : Valneva (United States)
ID : N/A

Références

Ann Agric Environ Med. 2012;19(2):271-4
pubmed: 22742800
Lancet Infect Dis. 2023 Oct;23(10):1186-1196
pubmed: 37419129
Diagnostics (Basel). 2021 Nov 21;11(11):
pubmed: 34829504
Przegl Epidemiol. 2022;76(3):
pubmed: 36524881
Emerg Infect Dis. 2021 Aug;27(8):2017-2024
pubmed: 34286689
Vector Borne Zoonotic Dis. 2023 Apr;23(4):195-220
pubmed: 37071401
Arch Dermatol. 2006 Jul;142(7):862-8
pubmed: 16847202
Emerg Infect Dis. 2011 Jan;17(1):7-15
pubmed: 21192848
Eur J Clin Microbiol Infect Dis. 2019 Feb;38(2):201-208
pubmed: 30456435
Ticks Tick Borne Dis. 2016 Feb;7(1):71-79
pubmed: 26341726
PLoS One. 2020 Mar 2;15(3):e0226766
pubmed: 32119685
J Autoimmun. 2015 Feb;57:82-115
pubmed: 25451629
Vector Borne Zoonotic Dis. 2023 Apr;23(4):265-272
pubmed: 37071408
Emerg Infect Dis. 2011 Jan;17(1):16-22
pubmed: 21192849
J Clin Microbiol. 1994 Jun;32(6):1519-25
pubmed: 8077398
Vector Borne Zoonotic Dis. 2023 Apr;23(4):172-194
pubmed: 37071407
Clin Infect Dis. 2001 Sep 15;33(6):780-5
pubmed: 11512082
MMWR Morb Mortal Wkly Rep. 2019 Aug 16;68(32):703
pubmed: 31415492
Public Health. 2023 Jun;219:1-9
pubmed: 37075486
Zoonoses Public Health. 2023 Nov;70(7):647-655
pubmed: 37458418
Epidemiol Infect. 2010 Jun;138(6):802-12
pubmed: 19765352
Ann Agric Environ Med. 2008;15(2):327-32
pubmed: 19061271
Microorganisms. 2020 Nov 25;8(12):
pubmed: 33255673
Ann Agric Environ Med. 2012;19(2):203-7
pubmed: 22742788
BMC Public Health. 2014 Feb 11;14:147
pubmed: 24517715
PLoS One. 2013 Nov 21;8(11):e81433
pubmed: 24278437
PLoS One. 2013 May 16;8(5):e64361
pubmed: 23696884
Emerg Infect Dis. 1999 Sep-Oct;5(5):607-25
pubmed: 10511517
Vector Borne Zoonotic Dis. 2023 Apr;23(4):247-255
pubmed: 37071404
Med Pr. 2014;65(1):109-17
pubmed: 24834698
Vector Borne Zoonotic Dis. 2023 Apr;23(4):142-155
pubmed: 37071402
Emerg Infect Dis. 2009 Dec;15(12):2004-7
pubmed: 19961687
J Infect Dis. 2003 Apr 15;187(8):1178-86
pubmed: 12695996
Ann Agric Environ Med. 2013;20(1):21-9
pubmed: 23540208
JAMA Netw Open. 2021 Jan 4;4(1):e2033706
pubmed: 33399860
Emerg Infect Dis. 2021 Apr;27(4):
pubmed: 33755546

Auteurs

Emily Colby (E)

Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.

Julia Olsen (J)

Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.

Frederick J Angulo (FJ)

Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.

Patrick Kelly (P)

Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.

Kate Halsby (K)

Pfizer Vaccines, Tadworth, Surrey KT20 7NS, UK.

Andreas Pilz (A)

Vaccines, Pfizer Corporation Austria, 1210 Vienna, Austria.

Urszula Sot (U)

Vaccine Medical Affairs, Pfizer Poland Inc., 02-092 Warsaw, Poland.

Tomasz Chmielewski (T)

National Institute of Public Health, 00-791 Warsaw, Poland.

Katarzyna Pancer (K)

National Institute of Public Health, 00-791 Warsaw, Poland.

Jennifer C Moïsi (JC)

Pfizer Vaccines, 75014 Paris, France.

Luis Jodar (L)

Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Collegeville, PA 19426, USA.

James H Stark (JH)

Vaccines, Antivirals, and Evidence Generation, Pfizer Biopharma Group, Cambridge, MA 02139, USA.

Classifications MeSH